MedCity – Fantastic news for pharma, but how will it be implemented?

MedCity - Fantastic news for pharma, but how will it be implemented?Last week, Boris Johnson announced the launch of MedCity, a partnership of the UK’s top scientists, life science companies, and investors across London, Cambridge and Oxford.

MedCity was set up by the Mayor and King’s Health Partners, Imperial College Academic Health Science Centre and UCL partners, with Oxford and Cambridge universities, and will be supported by a panel of experts.

The new collective aims to spur the discovery of treatments to fight a number of diseases, such as cancer, diabetes and dementia.

Within the last ten years, the employment levels within the UK life sciences sector have grown by 21%, with over 700,000 people employed in the life sciences sector in the South East.

Boris Johnson commented that the collaboration between London, Oxford and Cambridge, will “form a ‘golden triangle’ of scientific innovation” allowing the UK to “channel that intellectual pre-eminence into a positive impact on our economy.”

Within the announcement, Boris Johnson noted that MedCity is expected to generate thousands of new jobs within the life sciences sector, and to eventually “rival the financial services sector” in the UK economy.

As Europe’s leading independent pharmaceutical staffing company, the Clinical Professionals Group welcomes the launch of MedCity as fantastic news for the life sciences sector, as the industry strives to find new treatments to combat multiple diseases.

However, as of yet there has been no announcement regarding how MedCity will be implemented, and how the project will be staffed.  With the big increase in new jobs expected, the success of MedCity will be heavily dependent on how the recruitment for these new jobs is managed, and the level of training and support that is provided to the new employees after they have been recruited.

Yvette Cleland, Managing Director of The Clinical Professionals Group commented: “This is an outstanding initiative, however, unless the MedCity Board collaborates closely with the UK Life Sciences staffing industry, universities and training institutes these newly created positions will not be filled due to a vast lack in skilled labour and this exceptional opportunity for the UK Life Sciences industry will fail at the first hurdle.”

The initial £4 million of funding for MedCity will be financed by the Higher Education Funding Council and City Hall, allowing the promotion of MedCity as a leading hub for the life sciences sector globally, allowing it to compete with the science hubs of Boston, Singapore and Shanghai.

Source

Cytos’ CYT003 Fails to Achieve Clinical Trial Endpoint

Cytos’ CYT003 Fails to Achieve Clinical Trial EndpointCytos Biotechnology yesterday announced that their Phase IIb clinical study of CYT003 failed to meet its primary or secondary endpoints.

The clinical trial tested patients with moderate to severe allergic asthma, and showed that the immune modulator did not achieve a statistically significant reduction of the Asthma Control Questionnaire (ACQ) score at week 12 in comparison to placebo.

Cytos has consequently decided to unblind and terminate the clinical study, rather than pursue their previous plan to continue with a blinded observation period for 9 months.

Continue reading

Pharmaceutical Job Digest

Job SearchAre you searching for a new pharmaceutical job? Click on the links below to view some of the latest job vacancies that we are recruiting for:

Regulatory Affairs
Regulatory Affairs Junior Project Manager – UK
Regulatory Affairs Liaison Director – UK
Regulatory Affairs Programme Manager – UK
Regulatory Affairs Consultant – UK
Regulatory Affairs Manager – UK

Clinical Research
Senior Project Manager – Spain
Clinical Project Line Manager – UK

Quality Assurance / Quality Control
Artwork and Change Control Systems Manager – UK
Head of Quality Management – UK

Pharmacovigilance / Drug Safety
Senior Pharmacovigilance Business Analyst – UK
Pharmacovigilance Executive – UK
Pharmacovigilance Manager – UK

Medical Devices
Senior Regulatory Affairs Officer – UK
Regulatory Affairs Specialist – UK
Quality Assurance & Regulatory Affairs Associate – UK
Regulatory Affairs Senior Executive, QMS & Technical – UK

Commercial
Communications Manager – UK

Biometrics
SAS Programmer – Switzerland

These job opportunities not right for you? Register your CV with us to be contacted when we receive pharmaceutical jobs that suit you!

Alternatively, visit our job vacancies page for all the job vacancies that we are currently recruiting for.

Pharmaceutical Job Vacancy Digest

Job SearchAre you searching for a new job? Click on the links below to view some of the latest pharmaceutical jobs that The Clinical Professionals Group are recruiting for:

Commercial
EMEA Marketing Director – UK
Senior Brand Manager, Immunology – UK
Senior Brand Manager, Oncology – UK
Senior Manager, Analytics – UK
Pharmaceutical Technical Specialist – UK

Clinical Research
Clinical Study Management / Trial Coordination – UK
Senior Clinical Research Associate (SCRA) – UK

Market Access
Reimbursement & Market Access Manager – UK

Regulatory Affairs
Senior Associate Regulatory Affairs, CMC / Clinical Writing – UK
Senior Regulatory Affairs Consultant, Strategic Background – UK
Operations Manager Regulatory Affairs – UK
Senior Project Manager, Regulatory Affairs – UK
Regulatory Affairs Manager – UK

Medical Affairs / Medical Science Liaison (MSL)
Scientific Advisor – UK
Medical Science Liaison (MSL) – UK
Medical Services Executive (Medical Information) – UK
Patient Monitoring Field Advisor – UK
Medical Science Liaison, Oncology – UK

Medical Communications
Medical Writer – UK
Creative Medical Writer (Copywriter) – UK

Are these job vacancies not right for you? Register your CV with us to be contacted when we receive jobs that suit you!

Alternatively, visit our job vacancies page for a list of all the pharmaceutical job vacancies that we are currently recruiting for.

Clinical Professionals Achieve Record Breaking Month

Clinical Professionals Achieve Record Breaking MonthThe Clinical Professionals Group has achieved a record breaking March with the highest number of “placed candidates” in a one month period, in the group’s history.

This record breaking month aptly highlights The Clinical Professionals Group’s growth and success, particularly over the last 12 months with the continued expansion of our EU teams and functional expertise with the launch of Regulatory and Medcomms Professionals.  This puts the company firmly on track to achieve the company’s Mission Statement “to double turnover by 2015 by diversification of services, geographic expansion and investment in our people.”

Clinical Professionals’ Managing Director, Yvette Cleland commented:
“As the business has continued to grow and expand, so has the expertise, drive and talent of all Clinical Professionals team members.  Few businesses can boast such high calibre and committed staff and I believe this is why we have achieved these previously unparalleled placed candidates.  I feel honoured to work with such an incredible group of people and seeing such exceptional levels of success and quality work with our candidates and clients alike.”

The Clinical Professionals Group consists of Clinical Professionals, Regulatory Professionals, Medcomms Professionals and Only Medics, and is Europe’s leading independent pharmaceutical staffing company.

Positive Results for Pfizer’s Lung Cancer Therapy, Xalkori

Postive Results for Pfizer’s Lung Cancer Therapy, XalkoriPfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy.

Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared to standard platinum-based chemotherapy regimens.

Continue reading

NICE Draft Guidance Rejects Bayer’s Xofigo

NICE Draft Guidance Rejects Bayer’s XofigoThe National Institute for Health and Care Excellence (NICE) today published draft regulatory guidance rejecting Bayer’s Xofigo for patients with prostate cancer.

Xofigo has been submitted to the regulatory body to treat patients with hormone relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases.

Clinical trials have demonstrated that Xofigo can significantly improve overall survival compared to a placebo.

Continue reading

Pharmaceutical job digest

Job SearchAre you searching for your next pharmaceutical job? Click on the links below to view some of the latest pharma jobs that Clinical Professionals are recruiting for:

Clinical Research
Clinical Manager – Neurology – UK
UK Affiliate Clinical Operations Manager – UK
Global Clinical Project Manager – UK
Clinical Research Associate \ CRA – UK
Study Start Up \ Clinical Trial Specialist – UK

Regulatory
Senior Regulatory Affairs Associate – UK
Regulatory Affairs Project Manager – UK
Regulatory Affairs Junior Project manager – UK
HUB Labelling Manager (French) – UK

Medical communications
MedComms Internships – UK
Production Manager – UK

Health economics / Market access
Healthcare Development Manager – UK

Commercial
UK Supply Coordinator (FMCG) – UK

Quality Assurance /Quality Control
Senior QA Specialist – UK
Quality Assurance Manager – UK

Are these roles not right for you? Remember to register your CV with us to be notified when we receive jobs that suit you!

Alternatively, you can visit our job vacancies page for a full list of all the pharmaceutical jobs that we are currently recruiting for.

Positive Phase III Clinical Results for Amgen’s PCSK9 Inhibitor

Positive Phase III Clinical Results for Amgen's PCSK9 InhibitorAmgen yesterday announced further positive clinical data for their novel cholesterol buster, evolocumab, putting it ahead in the race to get the first PCSK9 inhibitor to market.

The Phase III clinical trial of evolocumab, an injectable monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin kexin type 9), met the primary endpoint of percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).

The clinical study assessed the safety, tolerability and efficacy of evolocumab compared to placebo in 49 adults and adolescents (between 12 and 18 years old) with homozygous familial hypercholesterolemia who were on a stable dose of statin therapy and other lipid-lowering medication.

Continue reading

AstraZeneca’s Diabetes Drug, Xigduo, Launched in the UK

AstraZeneca’s Diabetes Drug, Xigduo, Launched in the UKType II diabetes patients living in England and Wales have gained access to a new treatment option to improve blood glucose levels after AstraZeneca launched their diabetes drug, Xigduo, earlier this week.

Xigduo combines Forxiga (dapagliflozin) and metformin in a twice-daily tablet for use in patients inadequately controlled on their current metformin-based treatment regimen, or who are being treated with both dapagliflozin and metformin as separate tablets.

Continue reading